Clinical Trial

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and safety of the combination therapy of SH006 injection in the treatment of advanced hepatocellular carcinoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-31.
Trial Details
NCT Number NCT07392866
Lead Sponsor Nanjing Sanhome Pharmaceutical, Co., Ltd.
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 120 participants
Start Date 2026-03-01
Primary Completion 2030-03-01 (estimated)
Study Completion 2030-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-09